DEVELOPMENT AND EVALUATION OF TIOCONAZOLE LOADED EMULGEL by Sah, Shailendra Kumar et al.
Original Article 
DEVELOPMENT AND EVALUATION OF TIOCONAZOLE LOADED EMULGEL 
 
SHAILENDRA KUMAR SAH*, ASHUTOSH BADOLA, SAYANTAN MUKHOPADHYAY 
Department of Pharmaceutics, Division of Pharmaceutical Sciences, Shri Guru Ram Rai Institute of Technology and Science, Uttarakhand 
Technical University, Dehradun, 248001, Uttarakhand, India 
Email: sahshailendra31@gmail.com 
Received: 17 May 2017, Revised and Accepted: 22 Aug 2017 
ABSTRACT  
Objective: The objective of the present work was to develop, characterize and evaluate the tioconazole loaded emulgel and to prove that emulgel 
can be the best alternative for delivery of hydrophobic drug topically. 
Methods: for the preparation of stable Emulgel, firstly gels were prepared using different polymers as carbopol 934 and xanthan gum, followed by 
preparation of emulsions and finally mixed together (table 1). Emulgel was evaluated for physical appearance, pH, spreadability, extrudability, 
viscosity, swelling index, dilution test, centrifuge test, drug content, in vitro release study, kinetic analysis of release data, antifungal activity and 
stability study for 3 mo. A comparative study was also performed between prepared emulgels with available marketed antifungal cream. 
Results: All evaluation parameters were in acceptable range with good physical appearance and the pH in the range of 5.5 to 6.8. The results show 
that the extrudability was in the range 15.63 to 35.27 g/cm2; with spreadability in range of 6.6 to 8.833 cm. swelling index of F3 was seen a 
maximum in 3 h of about 75.13%. The viscosity was in the range of 15240 to 56340 cps at 10 RPM. During in vitro release of all formulations, F1 and 
F5 showed a maximum in vitro drug release of 59.11% and 55.11% respectively in 8 h. The kinetic analysis of fitting the data in different model 
shows that the best formulation of F1 fits in the Higuchi model with regression coefficient (R2) of 0.998 and show non-fickian diffusion. The 
formulations were found stable. F1 and F5 provide a similar zone of inhibition like to market cream.  
Conclusion: Tioconazole emulgel provide the better platform for delivery of hydrophobic drug for topical route and so able to produce better 
patient compliance.  
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Topical drug delivery is the potential route to deliver the drug 
producing low side effect in comparison with any other dosage 
forms. Drug concentration can be optimized to low concentration 
due to lack of metabolic elimination of drug before reaching the 
targeted site [1]. There are various conventional dosage forms for 
topical applications as cream, ointment, gel, but they shows 
fluctuation in bioavailability of drugs and are associated with other 
limitation as gel is limited to deliver the hydrophilic drugs, similarly 
ointment are limited for hydrophobic drug, so recently there have 
been novel approaches in the topical delivery to control the 
fluctuation of drug and deliver it in a controlled manner as per our 
need and to reduce the limitation associated with conventional 
preparation also to improve their properties for patient compliance 
[2]. The new approach in the field of topical drug delivery is 
introduced to deliver the hydrophobic drug that can enjoy the 
gelling property and whose rate can be controlled named Emulgel. It 
is simply where emulsion of the drug is prepared and that are 
incorporated in the gel [3].  
Several antifungal agents are available in the market as cream, 
ointment, gel, powders, lotions etc. for dermatological preparations. 
Tioconazole is an antifungal agent of imidazole class which is used to 
treat infections caused by a fungus or yeast. Imidazoles having broad 
spectrum activity against dermatophytes, Candida and other fungi 
involved in deep mycosis, some gram-positive and anaerobic 
bacteria. Tioconazole has considerably greater fungicidal activity 
than clotrimazole, econazole, ketoconazole, and miconazole against 
Candida albicans and other Candida species. tioconazole is highly 
hydrophobic in nature that lies in Biopharmaceutical classification 
system (BCS)-II class [4, 5].  
Taking above consideration, tioconazole was selected to formulate 
as emulgel, the aim of this study was to develop an emulgel 
formulation of tioconazole using two polymers, natural polymer-
xanthan gum and synthetic polymer-carbopol 934 in different 
concentration. The effect of using different polymer for gelling and 
its concentration variation on the release of the drug from the 
emulgels was investigated. Others parameters as physical 
properties, spreadability, rheological properties, extrudability, 
swelling index, antifungal activity of the emulgel were also evaluated 
and compared with the marketed cream of sertaconazole nitrate 
(Onabet TM) of the same imidazole class antifungal to justify that the 
emulgel can be the alternative for cream or they can be better 
dosage form to deliver the drug than other conventional semi-solid 
preparations for hydrophobic drugs in topical treatment.  
MATERIALS AND METHODS 
Materials  
Tioconazole was received as gift from Themis Medicare Pvt. Ltd. 
Haridwar (India). All other excipients were of analytical grade 
procured from Central drug house Pvt. Ltd. Delhi (India). Distilled 
water was used throughout the studies. Onabet TM cream 
[sertaconazole nitrate 2% w/w] of Glenmark Pharmaceuticals Ltd 
was procured from Pharmacy shop. 
Methods  
Drug-polymer compatibility studies  
Drug–polymer compatibility studies were done for selection of 
polymer by Fourier Transform Infrared spectroscopy (FTIR) [6]. 
Infrared spectroscopy  
Infrared spectra were recorded in the region of 4000 to 400 cm-1by 
Perkin Elmer Spectrum Two™ Spectrophotometer. 
Formulation and evaluation 
Preparation of emulgel formulation in different polymer 
The composition of emulgel formulations is given in table 1. Emulgel 
was prepared in two steps, the first formation of emulsion than the 
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addition of emulsion into the gel. In formulations F1, F2, F3 gel base 
were prepared by dispersing carbopol 934 in distilled water and the 
pH was adjusted to 6 to 6.5 using triethanolamine (TEA). In 
formulations F4, F5, F6 xanthan gum was dispersed in cold water to 
form a gel. Oil phase of the emulsion was prepared by heating liquid 
paraffin and cetosteryl alcohol to 70 °C to 80 °C and dissolving span-
80 into it, then isopropyl myristate was added to oil phase. The 
aqueous phase is prepared by dissolving tween-80 and addition of 
propylene glycol to it, further tioconazole dissolved in alcohol was 
added to same. Both the oil and aqueous phase was heated to 70 °C 
to 80 °C and then the aqueous phase was added to oil under constant 
stirring until the temperature reaches to room temperature. The 
obtained emulsion was then added to Gel under stirring in the ratio 
of 1:1 to obtain the Emulgel [7]. 
 
Table 1: Composition of tioconazole emulgel formulations 
Ingredients (%w/w) Formulations  
F1 F2 F3 F4 F5 F6 
Tioconazole 1 1 1 1 1 1 
Carbopol 934 0.5 1 1.5 -- -- -- 
Xanthan gum  -- -- -- 1 1.5 2 
Light liquid paraffin 7 7 7 7 7 7 
Span 80 1 1 1 1 1 1 
Cetosteryl alcohol  3 3 3 3 3 3 
Isopropyl Myristate 7 7 7 7 7 7 
Tween 80 1 1 1 1 1 1 
Propylene glycol 5 5 5 5 5 5 
Ethanol  2.5 2.5 2.5 2.5 2.5 2.5 
Water q. s q. s q. s q. s q. s q. s 
 
Evaluations of emulgel and marketed cream  
Physical appearance 
The prepared Emulgel and the marketed cream Onabet TMwere 
inspected visually for their color, homogeneity, grittiness, phase 
separation [8].  
pH 
pH of 1% dispersion of Emulgel and the marketed cream Onabet TMin 
distilled water was measured with digital pH meter. Measurement 
was done in triplicate and averages were calculated [8].  
Extrudability (tube test) 
Here the weight required extruding 0.5 cm ribbon of Emulgel and 
the marketed cream Onabet TM in 10 s from the lacquered collapsible 
aluminum tube is determined. The test was repeated and the 
average values were used for the calculation [8]. 
Formula for extrudability calculation 
Extrudability = weight applied to extrude emulgel from tube(g)
/Area(cm2) 
Swelling index 
1 g of Emulgel formulations and the marketed cream Onabet TMwas 
taken on porous aluminum foil and then placed in the petri dish 
containing 10 ml distilled water. The samples were taken from the 
petri dish at a different time interval and left undisturbed in a dry 
place for some time so that the external liquid is removed and 
weighed. Swelling index is then calculated by using below formula [8].  
Swelling Index (SW)% = [(Wt − Wo)/Wo] × 100 
Where (SW) % = Equilibrium percent swelling,  
Wt = Weight of swollen emulgel after time t,  
Wo = Original weight of emulgel at zero time 
Spreadability  
It expresses the extent of the area to which formulation readily 
spreads to the affected part on the application. The therapeutic 
efficacy of the product depends on its spreading value. For 
determination of spreadability, 1 g of Emulgel formulations and the 
marketed cream Onabet TMwas placed within the circle of 1 cm 
diameter pre-marked on a glass plate of 20 x 20 cm, on which a 
second glass plate was placed. A 500 g weight was allowed to rest on 
the upper glass plate for 5 min. the increase in the diameter due to 
gel spreading was noted [9]. 
Drug content 
1% dilution of Emulgel formulations was done with a suitable 
solvent and filtered through Whatman filter paper. 1 ml filtrate is 
further diluted to 10 ml, then the sample was analyzed in UV 
spectrophotometer against blank that is solvent without drug and 
absorbance was noted. The absorbance was fitted in the line of 
equation obtained from the calibration curve to obtain the 
concentration of drug [10]. 
Dilution test 
1% aqueous dilution of Emulgel and the marketed cream Onabet 
TMwas done by adding Continuous phase and visually checked for 
phase separation and clarity [11].  
Centrifuge test  
6 g of Emulgel was taken in 10 ml graduated centrifuge tubes and 
were subjected to spin at 4000 RPM for 10 min. The sample was 
observed for any phase separation occurrence [12]. 
Viscosity  
The viscosity of prepared emulgel and Onabet TM marketed cream was 
measured by Brookfield DVE viscometer (AMETEK) with spindle 64. 
The preparation whose viscosity was to be determined was placed in 
the beaker and allowed to settle down at the room temperature. The 
spindle was then lowered down and rotated at 2, 5, 10, and 12 rpm. 
The viscosity in centipoises was observed and reported [13]. 
In vitro drug release  
In vitro releases of emulgel were calculated out using Franz diffusion 
cell (effective diffusion area 4.9 cm2 and 14 ml cell volume). Semi 
permeable egg membrane was clamped to the donor compartment 
and the receptor compartment was filled with phosphate buffer pH 
5.5+methanol [9:1] which was the dissolution media. The 
temperature of the cell was maintained at 37±2 °C. The medium was 
continuously stirred with the magnetic bead at 50 rpm. The emulgel 
(500 mg) were spread uniformly on the membrane. The sample 1 ml 
aliquots were withdrawn from the receptor at regular interval and 
replace with the equal amount of fresh dissolution media. The 
samples withdrawn were diluted to required and analyzed under 
UV-spectrophotometry. The cumulative percentage drug released 
were calculated with time [14]. 
Kinetic analysis of drug release  
Kinetic analysis of the drug release was done by fitting the release 
data to the different release model given below to describe the 
proper release model:  
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Zero order release (cumulative % drug release vs. time) 

	  	 
Where Q is the amount of drug released at time t, K0 is the zero–
order release rate. 
First order release (log cumulative % drug retained vs. time)  
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 	 		100–1 
Where Q is the percent of drug released at time t, K1 is the first–
order release rate constant. 
Higuchi model (cumulative % drug retained vs. square root of 
time) 
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Where Q is the percent of drug released at time t, K2 is the Higuchi 
square root of time release constant.  
Korsmeyer-peppas model (log cumulative % drug release v/s. 
log time) 
 	   	
 
Where F is fraction of drug released at time t, Mt is drug release at 
time t, M is the total amount of drug in dosage form, Km is a constant 
dependent on the geometry of the dosage form, n is diffusion 
exponent indicating the mechanism of drug release, if the value of n 
is 0.5 it indicates fickian diffusion and if between 0.5 to 1 it is 
anomalous transport or Non-fickian diffusion [14].  
Antifungal activity  
19.5 g of Potato dextrose agar (PDA) was transferred in a 500 ml of 
conical flask and 500 ml of purified water and heat is applied to 
dissolve completely. Sterilization was done for 15 min at 121 °C at 15 
lbs pressure in an autoclave. Agar well method was used to determine 
the zone of inhibition for antifungal activity of emulgel formulations. 
Aspergillus strain was obtained from the Department of Microbiology, 
self-cultured in SGRRITS, Dehradun. The medium was poured into the 
three petridish and cooled for few minutes at room temperature until 
it forms solidifies at room temperature and then the three cups are 
bored in each petridish with the help of sterile steel boarer of 6 mm 
and fungal strain was swabbed on the PDA plate and similar 
concentration of the standard formulation (0.125 g) and emulgel 
formulations (0.25 g) were placed in the bores with help of 18 gauges 
needles and the petri plates were incubated for 24 to 48 h at 25 °C in 
incubators. The zone of inhibition was measured in mm [15]. 
Stability studies  
The optimized formulation was subjected to accelerated stability for 
3 mo as per ICH guidelines by keeping at 40+2 °C/75+5% RH and 
Samples were withdrawn on at a regular interval of 1, 2 and 3 mo for 
evaluation of physical appearance, pH, viscosity, centrifuge test and 
drug content [16].  
RESULTS AND DISCUSSION  
Drug-polymer compatibility studies 
FTIR study of pure Drug (fig. 1), Drug with carbopol 934 (fig. 2) and 
drug with xanthan gum (fig. 3) was performed. The evaluation was 
based on shifting of the fingerprint region as the experimental result 
shows there was no significant deviation between drug and drug 
with polymers which confirm the compatibility. So these polymers 
were selected for formulations [6]. 
Evaluation of emulgel and marketed Cream 
Physical appearance 
Physical appearances of the formulations are shown in fig. 4 and 
described in table 2. 
  
 
Fig. 1: FTIR of tioconazole sample 
 
 
Fig. 2: FTIR-spectrum of tioconazole+carbopol 934 
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Fig. 3: FTIR spectrum of tioconazole+xanthan gum 
 
Table 2: Physical characteristics 
Formulation  Colour  Phase separation  Grittiness 
F1 White No  None 
F2 White  No  None  
F3 White No None 
F4 White No None 
F5 White No  None 
F6 White No  None 
Onabet TM White No  None 
* n=3, Average of three determinations 
 
 
Fig. 4: Different emulgel formulations 
 
The formulations were white viscous creamy preparation with a 
smooth, homogeneous texture and glossy appearance with no 
grittiness and phase separation. That indicates the physical 
stability of the prepared formulations with acceptable features 
[7]. 
pH  
PH of different formulations is listed in table 3. 
Extrudability  
Extrudability of the different formulation is shown in table 4. 
 
Table 3: pH of emulgel formulation and marketed cream 













* n=3, mean±SD, The pH of the formulations was in the range 5.5 to 6.8 which match with the normal pH range of the skin and thus do not produce 
any skin irritation [1].  
 
Table 4: Extrudability of emulgel formulations and marketed cream 
Formulation F1 F2 F3 F4 F5 F6 Onabet TM 














* n=3, mean±SD 
 
Formulation F1 and F4 with polymers carbopol 934 and xanthan 
gum respectively having low concentration among their respective 
formulations shows the low requirement of extrusion pressure 
and the extrudability rises with the increase in viscosity of the 
formulation. The formulation with xanthan gum requires low 
extrusion pressure in comparison with that of carbopol and all the 
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results were acceptable in comparison to the marketed cream 
Onabet TM [2]. 
Swelling index 
The swelling index of all formulations and marketed cream is 
represented in fig. 5. 
Formulations with carbopol 934 showed maximum swelling index in 
comparison with xanthan gum and were comparable to that of 
marketed cream. Among all the formulation, F3 emulgel with 
carbopol 934 (1.5%) showed the highest swelling index. Variation in 
swelling index value may be dependent on the water uptake nature 
and chain strength of the polymer [1]. 
Spreadability 
Spreadability of emulgel and marketed cream are shown in table 5. 
Spreadability is carried out for all the formulations. It indicates 
how easily the emulgel will be spread on the affected area by the 
small amount of shear. Spreadability of emulgel formulation lies 
between .1-8.833. F1 shows good spreadibility among the 
carbopol polymer and F4 shows good spreadibility among the 
xanthan gum polymer [9]. 
Drug content 
Drug content of prepared formulations are shown in table 6. 
 
 
Fig. 5: % swelling of formulated emulgels and marketed cream 
 
Table 5: Spreadability of emulgel formulations and marketed cream 
Formulation F1 F2 F3 F4 F5 F6 Onabet TM 














* n=3, mean±SD 
 
Table 6: Drug content of emulgel formulations 
Formulation F1 F2 F3 F4 F5 F6 












* n=3, mean±SD 
 
The drug content of the formulations is determined by UV-
spectrophotometer at a wavelength of 230 nm, all the formulations 
shows the drug content in between the limit of 95% to 102% and 
there is no major effect of a change in polymers and its 
concentrations [10]. 
Dilution test 
All prepared formulations and marketed cream were diluted with 
water and result indicated no phase separation upon dilution [11].  
Centrifuge test  
All prepared formulations and marketed cream showed no phase 
separation that indicates the stability of product on high shear rate [12].  
Viscosity 
The viscosity of emulgel formulation and marketed cream was 
determined using Brookfield Viscometer. Emulgel with carbopol 934 
shows high viscosity in comparison to that of emulgel with xanthan 
gum. Results show the ascending viscosity of emulgel with an 
increase in the concentration of polymer in order F3>F2>F1 for 
carbopol 934, and a similar increase in viscosity was seen for the 
formulation with xanthan gum F6>F5>F4 as the concentration of 
polymer increases. Marketed cream Onabet TM shows viscosity 
comparable to emulgel formulation F1. Formulation shows decrease 
in viscosity with an increase in shear rate from 2 to 12 RPM that 
confirms the shear thinning properties of the formulations [13]. 
In vitro drug release study 
Release of drug from the formulation was depended to the nature 
and concentration of polymer. Formulations with carbopol 934 
shows the drug release in descending order F1>F2>F3 where the 
amount of drug released after 8 h was 59.11%, 40.77%, 35.18% 
respectively, and for the formulations with xanthan gum the drug 
release in descending order F5>F4>F6 where the amount of drug 
released after 8 h was 55.14%, 50.68%, 42.83% respectively. It has 
been concluded that the carbopol 934 emulgel with low 
concentration of polymer F1 shows maximum release. The release 
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pattern with carbopol 934 emulgel was better than that of xanthan 
Gum. It shows carbopol 934 is better polymer than xanthan gum for 
formulating emulgel. Formulation F1 from carbopol polymer and 
formulation F5 from xanthan gum polymer shows the best result. 
The cumulative % drug release profile of all the formulation batches 
has been shown in fig. 7 [16]. 
  
 
Fig. 6: Viscosity of emulgels and marketed cream with effects of shear rate (rpm) on it 
 
 
Fig. 7: In vitro cumulative % drug release profile of emulgel formulations 
 
Kinetic analysis of drug release 
The results of In vitro release from formulations were plotted in different 
kinetic models like Zero order, First order, Higuchi plot and Korsmeyer 
Peppas plot and are represented in fig. 8, fig. 9, fig. 10, fig. 11 
respectively. The regression coefficient value R2 is reported for all 
formulations. The release data of best formulation F1 and F5 follows 
Higuchi model kinetics and first order kinetics respectively. All the 
formulation follows anomalous or non fickian diffusion for drug release. 
The regression coefficients of all formulations are listed in table 7 [16]. 
 
 
Fig. 8: Zero order release plot of emulgel formulations 
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Fig. 9: First order release plot of emulgel formulations 
 
 
Fig. 10: Higuchi release plot of emulgel formulations 
 
 
Fig. 11: Korsmeyer peppas release plot of emulgel formulations 
 
Table 7: Release kinetic result of emulgel formulations 
Formulation Zero order First order Higuchi plot Korsmeyer Peppas plot Best fit model mechanism of drug release 
R2 R2 R2 R2 n 
F1 0.970 0.996 0.998 0.986 0.845 Higuchi model  Non-fickian 
F2 0.918 0.957 0.964 0.890 0.746 Higuchi model  Non-fickian 
F3 0.980 0.987 0.975 0.951 0.887 First order  Non-fickian 
F4 0.966 0.987 0.995 0.983 0.787 Higuchi model  Non-fickian 
F5 0.969 0.983 0.980 0.961 0.664 First order Non-fickian 
F6 0.983 0.977 0.953 0.973 0.730 Zero order Non-fickian 
 
Antifungal activity  
The antifungal activity of best two formulations F1 and F5 were seen 
and compared with the Onabet TM marketed cream (S) by measuring 
the zone of inhibition. The Formulation F1 shows a maximum zone 
of inhibition 18 mm, whereas F5 and S shows the zone of inhibition 
of 14.67 and 17.33 respectively. The result indicates that the 
prepared emulgel F1 and F5 had a comparable antifungal activity to 
that of marketed cream (S) [17]. 
  
Table 10: Zone of inhibition of emulgel formulation and marketed cream 
Formulation Zone of Inhibition(mm) 
F1 18±1.732 
F5 14.67±0.577 
S (Onabet TM cream) 17.33±1.155 
* n=3, mean±SD 
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Fig. 12: Showing zone of inhibition in formulation F1, F5and 
marketed preparation S 
 
Stability studies  
The optimized formulations F1 and F5 with acceptable drug release 
were observed in stability study, for 3 mo and all the parameters as 
physical appearance, pH, viscosity and drug content was found to be 
stable upon storage for 3 mo, no major changes were observed in 
their parameters, the slight changes were seen which was in 
acceptable limit that indicates, the formulations are stable whose 
shelf life can be predicted [16]. 
CONCLUSION  
Tioconazole Emulgel was formulated and compared with marketed 
cream and proved that emulgel can be, the better option than 
conventional as it minimizes the disadvantages associated with 
conventional semi-solid increasing the patient compatibility. The 
different gelling agent can be utilized such as carbopol 934 and 
xanthan gum. It can be novel approach to deliver the hydrophobic 
drug topically. It utilizes the two methods of formulating the 
emulsion and gel that facilitate to control the release of drugs. 
Various drugs can be formulated as emulgel and mostly the BCS 
class-II is efficient.  
From the result and discussion, it is concluded that the emulgel with 
different polymer was in the acceptable range, showing the 
acceptable result of physical appearance, pH, spreadability, 
extrudability, viscosity, swelling index, centrifuge test, dilution test, 
in vitro-release, antifungal activity and the formulation was found 
stable. However, among all formulations, F1 and F5 shows better 
result and concluded that tioconazole emulgel can be used for 
topical drug delivery with the aim of better efficacy. Among the 
polymer selection, the formulation with carbopol 934 with low 
concentration emulgel has better performances in comparison to 
xanthan gum. From the in vitro drug release studies, formulation F1 
with carbopol 934 and formulation F5 with xanthan gum showed 
the maximum drug release of 55.91% and 55.14% respectively in 8 
h with good physical properties. From the stability studies, after 
storage, the F1 and F5 formulation was observed in a stable form. 
Thus the tioconazole emulgel can be the best approach for topical 
delivery. 
Recently only fewer drugs are being marketed as emulgel so there is 
open scope to utilize the emulgel as drug delivery system. Being 
simple to formulate they can be widely accepted by Researcher. 
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